Home › Critical Illness › NCT07694206

Digital and Plasma Biomarkers in Delirium

Delirium Evaluation With Longitudinal Tau Assessment

Who can join

Ages 65 and older · All sexes

Inclusion Criteria:

* Admitted to the intensive care unit
* Able to consent or have a legally authorized representative consent on their behalf
* English speaker
* Expected ICU stay of 48 hours or more

Exclusion Criteria:

* Advanced dementia
* End stage liver disease
* Renal replacement therapy
* Structural brain injury, including but not limited to traumatic brain injury, cerebrovascular accident and intracranial hemorrhage,

About the study

The goal of this observational study is to learn if there are potential digital and plasma-based biomarkers that could help detect, predict, and prognosticate delirium in older adult patients who are admitted to the intensive care unit (ICU). The main question DELTA aims to answer is:

Can digital biometrics predict and detect delirium in older adult ICU patients? Do biomarkers of neurodegeneration fluctuate in ICU patients in such a way that delrium could potentially be predicted?

Participants admitted o the ICU will wear a digital device to collect biometric data and will have serial plasma samples collected during ICU admission and patients will be also assessed for delirium daily by study staff.

Sponsor: Scripps Health · Participants: 100 · Started: May 28, 2026

Contact the study team

• Stuti Jaiswal, MD, PhD · Phone: 858-554-9100

Official record on ClinicalTrials.gov — NCT07694206

Locations in the U.S.

Conditions

• Critical Illness
• Insomnia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.